What’s the current market cap for Becton Dickinson stock?

Becton Dickinson (BDX) has a market cap of $40B as of May 22, 2026.

What is the P/E ratio for Becton Dickinson stock?

The price to earnings (P/E) ratio for Becton Dickinson (BDX) stock is 36.7 as of May 22, 2026.

Does Becton Dickinson stock pay dividends?

Yes, the Becton Dickinson (BDX) stock pays dividends to shareholders. As of May 22, 2026, the dividend rate is $4.18 and the yield is 2.87%. Becton Dickinson has a payout ratio of 104.04% on a trailing twelve-month basis.

When is the next Becton Dickinson dividend payment date?

The next Becton Dickinson (BDX) dividend payment is scheduled for June 30, 2026.

What is the beta indicator for Becton Dickinson?

Becton Dickinson (BDX) has a beta rating of 0.29. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy Becton Dickinson stock | $BDX Share Price

13:30

15:10

16:45

18:25

20:00

About Becton Dickinson

Becton Dickinson operates in four business units. Medical essentials (35% of total sales) includes the legacy medical surgical unit, which sells catheters, syringes, and infection prevention products. Connected care (24%) core products include the Alaris infusion pump, Pyxis dispensing system, and pharmacy automation platforms. Biopharma systems (13%) produces prefillable syringes and autoinjectors. Interventional (29%) is composed of the surgery, peripheral vascular, and urology segments. More than 60% of revenue comes from the United States.

Ticker

$BDX

Sector

Health

Primary listing

NYSE

Employees

72,000

Headquarters

Franklin Lakes, United States

Website

www.bd.com

Becton Dickinson Metrics

BasicAdvanced

$40bn

36.70

$3.99

0.29

$4.18

2.87%

What the Analysts think about Becton Dickinson

Analyst ratings (Buy, Hold, Sell) for Becton Dickinson stock.

Bulls say / Bears say

BD reported Q1 FY26 revenue of $5.3 billion, up 1.6% year-over-year and ahead of the $5.15 billion consensus estimate, thanks largely to strength in the Connected Care segment. (Reuters)

BD completed the spin-off of its Biosciences & Diagnostic Solutions unit and merger with Waters Corporation in February 2026, unlocking a $4 billion cash distribution for faster share buybacks and debt reduction, while sharpening its focus on high-margin MedTech operations. (S&P Global)

The HemoSphere Stream™ Module, scheduled for launch in the first half of FY26, is set to expand BD’s addressable market almost tenfold to 300,000 monitors, highlighting a strong pipeline of new products. (Investing.com)

BD's Q1 FY26 adjusted operating margin decreased to 21.2%, falling 240 basis points year-over-year, as a result of margin pressure from tariffs and inflation-driven cost increases. (Investing.com)

BD’s full-year FY26 adjusted EPS guidance of $12.35–$12.65 was far below the analyst consensus of $14.94, sending shares down nearly 3% as investors reacted to the cautious outlook. (Investing.com)

In December 2025, BD expanded its Class I voluntary recall of certain BD Alaris™ pump infusion sets to include 15 more models, underlining ongoing quality control issues that may add to costs and hurt the company’s reputation. (FDA)

Data summarised monthly by Lightyear AI. Last updated on 25 Apr 2026.

Becton Dickinson Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

Becton Dickinson Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $BDX

Capital at risk

Market closed

Upcoming events

Bulls say / Bears say

BD reported Q1 FY26 revenue of $5.3 billion, up 1.6% year-over-year and ahead of the $5.15 billion consensus estimate, thanks largely to strength in the Connected Care segment. (Reuters)

BD's Q1 FY26 adjusted operating margin decreased to 21.2%, falling 240 basis points year-over-year, as a result of margin pressure from tariffs and inflation-driven cost increases. (Investing.com)

Data summarised monthly by Lightyear AI. Last updated on 25 Apr 2026.